Products

Covis Pharmaceuticals is proud to provide products that treat life-threatening conditions
and chronic illnesses.


Fortaz and Zinacef are registered trademarks of the GlaxoSmithKline group of companies.
Zantac is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc, used under license.

Fortaz® (ceftazidime for injection)
Fortaz® (ceftazidime for injection) Fortaz (ceftazidime for injection) is a semisynthetic, broad-spectrum, ß-lactam antibiotic indicated for the treatment of patients with infections caused by susceptible strains in the following diseases:

Click here to view Full Prescribing and Important Safety Information
  • Lower respiratory tract infections
  • Skin and skin-structure infections
  • Urinary tract infections
  • Bacterial septicemia
  • Bone and joint infections
  • Gynecologic infections
  • Intra-abdominal infections
  • Central nervous system infections
(See the Indications and Usage section of the complete Prescribing Information for a listing of the specific bacterial strains for which FORTAZ is indicated to treat for each of the aforementioned diseases.)

Important Safety Information about FORTAZ

FORTAZ is contraindicated in patients who have shown hypersensitivity to ceftazidime or the cephalosporin group of antibiotics.

Before therapy with FORTAZ is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to ceftazidime, cephalosporins, penicillins, or other drugs. If FORTAZ is to be given to penicillin-sensitive patients, caution should be exercised because cross-hypersensitivity among beta-lactam antibiotics has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction to FORTAZ occurs, its use should be discontinued. Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures, including oxygen, IV fluids, IV antihistamines, corticosteroids, pressor amines, and airway management as clinically indicated.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including FORTAZ, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. CDAD must be considered in all patients who present with diarrhea following antibiotic use, and careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

FORTAZ is generally well tolerated. The incidence of adverse reactions associated with the administration of ceftazidime was low in clinical trials. The most common were local reactions following IV injection and allergic and gastrointestinal reactions. Other adverse reactions were encountered infrequently. No disulfiram-like reactions were reported. (See the Adverse Reactions section of the complete Prescribing Information.)

Please see full Prescribing Information for FORTAZ.

Lanoxin, Fortaz, and Zinacef are registered trademarks of the GlaxoSmithKline group of companies.
Zantac is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc, used under license.

Zantac®
(ranitidine hydrochloride) Injection
Zantac (ranitidine hydrochloride) Injection is a histamine H2-receptor antagonist indicated for the treatment of some hospitalized patients with pathological hypersecretory conditions or intractable duodenal ulcers or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication.

Click here to view Full Prescribing and Important Safety Information

Important Safety Information about ZANTAC Injection and ZANTAC Injection Premixed

ZANTAC Injection and ZANTAC Injection Premixed are contraindicated in patients known to have hypersensitivity to the drug.

In controlled studies in normal volunteers, elevations in serum glutamic pyruvic transaminase (SGPT) have been observed when H2-antagonists have been administered intravenously at greater-than-recommended dosages for 5 days or longer. Therefore, in patients receiving IV ranitidine at dosages ≥100 mg 4 times daily for periods of 5 days or longer, SGPT levels should be monitored daily (starting on Day 5 of treatment) for the remainder of IV ranitidine therapy.

Bradycardia in association with rapid administration of ZANTAC Injection has been reported rarely, usually in patients with predisposing factors for cardiac rhythm disturbances; therefore, recommended rates of administration should not be exceeded (see the Dosage and Administration section of the complete Prescribing Information).

Rare reports suggest that ZANTAC may precipitate acute porphyric attacks in patients with acute porphyria. ZANTAC should, therefore, be avoided in patients with a history of acute porphyria.

Transient pain at the site of IM injection of ZANTAC has been reported. Transient local burning or itching has been reported with IV administration of ZANTAC. Headache, sometimes severe, seems to be related to the administration of ZANTAC.

Please see full Prescribing Information for ZANTAC Injection.

Fortaz and Zinacef are registered trademarks of the GlaxoSmithKline group of companies.
Zantac is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc, used under license.

Zinacef® (cefuroxime for injection)
Zinacef (cefuroxime for injection) is a semisynthetic, broad-spectrum, cephalosporin antibiotic indicated for the treatment of patients with infections caused by susceptible strains in the following diseases:

Click here to view Full Prescribing and Important Safety Information
  • Lower respiratory tract infections
  • Urinary tract infections
  • Skin and skin-structure infections
  • Septicemia
  • Meningitis
  • Gonorrhea
  • Bone and joint infections
(See the Indications and Usage section of the complete Prescribing Information for a listing of the specific bacterial strains for which ZINACEF is indicated to treat for each of the aforementioned diseases.)

Important Safety Information about ZINACEF

ZINACEF is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.

Before therapy with ZINACEF is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cephalosporins, penicillins, or other drugs. ZINACEF should be given cautiously to penicillin-sensitive patients. Antibiotics should be administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. If an allergic reaction to ZINACEF occurs, its use should be discontinued. Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures, including oxygen, IV fluids, IV antihistamines, corticosteroids, pressor amines, and airway management as clinically indicated.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including ZINACEF, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. CDAD must be considered in all patients who present with diarrhea following antibiotic use, and careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

ZINACEF is generally well tolerated. The most common adverse effects have been local reactions following IV administration. Other adverse reactions have been encountered only rarely. (See the Adverse Reactions section of the complete Prescribing Information.)

Please see full Prescribing Information for ZINACEF.

Fortaz and Zinacef are registered trademarks of the GlaxoSmithKline group of companies.
Zantac is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc, used under license.